| Attributes | Values |
|---|
| rdf:type
| |
| http://linked.open...gbank/description
| - A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has pellagra-curative, vasodilating, and antilipemic properties. [PubChem] (en)
|
| http://linked.open...y/drugbank/dosage
| |
| http://linked.open...generalReferences
| - # Gopal E, Fei YJ, Miyauchi S, Zhuang L, Prasad PD, Ganapathy V: Sodium-coupled and electrogenic transport of B-complex vitamin nicotinic acid by slc5a8, a member of the Na/glucose co-transporter gene family. Biochem J. 2005 May 15;388(Pt 1):309-16. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15651982 (en)
|
| http://linked.open...gy/drugbank/group
| - approved (en)
- nutraceutical (en)
- investigational (en)
|
| http://linked.open...drugbank/halfLife
| |
| http://linked.open...ugbank/indication
| - For the treatment of type IV and V hyperlipidemia. It is indicated as ajunctive therapy. (en)
|
| http://linked.open...bank/manufacturer
| |
| sameAs
| |
| Title
| |
| adms:identifier
| |
| http://linked.open...mechanismOfAction
| - Niacin binds to Nicotinate D-ribonucleotide phyrophsopate phosphoribosyltransferase, Nicotinic acid phosphoribosyltransferase, Nicotinate N-methyltransferase and the Niacin receptor. Niacin is the precursor to nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), which are vital cofactors for dozens of enzymes. The mechanism by which niacin exerts its lipid lowering effects is not entirely understood, but may involve several actions, including a decrease in esterification of hepatic triglycerides. Niacin treatment also decreases the serum levels of apolipoprotein B-100 (apo B), the major protein component of the VLDL (very low-density lipoprotein) and LDL fractions. (en)
|
| http://linked.open...drugbank/packager
| |
| http://linked.open...y/drugbank/patent
| |
| http://linked.open.../drugbank/synonym
| - Niacin (en)
- PP Factor (en)
- 3-Pyridinecarboxylic acid (en)
- Acide Nicotinique (en)
- Acidum Nicotinicum (en)
- M-Pyridinecarboxylic Acid (en)
- Nicotinic Acid (en)
- Vitamin B3 (en)
- 3-Pyridylcarboxylic acid (en)
- 3-carboxypyridine (en)
- Acido nicotinico (en)
- Anti-pellagra vitamin (en)
- Nikotinsaeure (en)
- P.P. factor (en)
- Pellagra preventive factor (en)
- Pyridine-beta-carboxylic acid (en)
- beta-Pyridinecarboxylic acid (en)
- pyridine-β-carboxylic acid (en)
- β-pyridinecarboxylic acid (en)
|
| http://linked.open...drugbank/toxicity
| - Nicotinic acid can cause vasodilation of cutaneous blood vessels resulting in increased blood flow, principally in the face, neck and chest. This produces the niacin- or nicotinic acid-flush. The niacin-flush is thought to be mediated via the prostaglandin prostacyclin. Histamine may also play a role in the niacin-flush. Flushing is the adverse reaction first observed after intake of a large dose of nicotinic acid, and the most bothersome one. LD<sub>50</sub> 7000 mg/kg (Rat) (en)
|
| http://linked.open.../drug/hasAHFSCode
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)